Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Dicot Pharma receives new patent in Europe for LIB-01

Uppsala, Sweden, October 26, 2026. Dicot Pharma AB has been granted a new patent in 25 European countries covering the manufacturing process for its drug candidate LIB-01. The patent strengthens the intellectual property protection for the drug candidate in an important market until 2043.

The new patent covers several steps in the manufacturing process for LIB-01 and is valid until 2043. It complements the company’s existing patent protection and strengthens the long-term intellectual property protection for the drug candidate.

Corresponding patents have previously been granted in other key geographic markets, including the US.

”A strong and long-term patent protection is an important part of our strategy for LIB-01. The new patent provides very broad geographic coverage in Europe until 2043. This is significant both for the continued development of LIB-01 and ahead of future commercialization”, says Elin Trampe, CEO of Dicot Pharma.

Datum 2026-10-26, kl 09:00
Källa MFN